1980 - Fellow of the American Psychological Association (APA)
His main research concerns Anesthesia, Pharmacology, Psychiatry, Drug and Caffeine. His Anesthesia study incorporates themes from Placebo, Benzodiazepine and Nicotine. His Placebo research is multidisciplinary, incorporating perspectives in Oral administration, Psychopharmacology and Mood.
His work in the fields of Sedative, Self-administration and Secobarbital overlaps with other areas such as Breaking point. His Drug study combines topics from a wide range of disciplines, such as Euphoriant, Energy and Environmental health. His Caffeine research is multidisciplinary, incorporating elements of Craving, Drug tolerance, Physiology and Physical dependence.
Roland R. Griffiths mainly focuses on Anesthesia, Pharmacology, Placebo, Psychiatry and Drug. The study of Anesthesia is intertwined with the study of Benzodiazepine in a number of ways. His research integrates issues of Antagonist, Drug discrimination, Lorazepam and Caffeine in his study of Pharmacology.
His Caffeine research incorporates themes from Reinforcement and Physiology. As part of the same scientific family, he usually focuses on Placebo, concentrating on Audiology and intersecting with Developmental psychology. Roland R. Griffiths has researched Psilocybin in several fields, including Psychotherapist and Clinical psychology.
His primary scientific interests are in Psilocybin, Psychiatry, Hallucinogen, Clinical psychology and Caffeine. His Psilocybin research includes elements of Psychotherapist, Distress and Social psychology, Mood. His Hallucinogen study is concerned with the field of Pharmacology as a whole.
Roland R. Griffiths is interested in Drug, which is a field of Pharmacology. While the research belongs to areas of Clinical psychology, he spends his time largely on the problem of Psychedelic experience, intersecting his research to questions surrounding Psychedelic drug. His studies deal with areas such as Anesthesia and High doses as well as Triazolam.
Psilocybin, Hallucinogen, Psychedelic therapy, Psychiatry and Clinical psychology are his primary areas of study. His biological study spans a wide range of topics, including Psychotherapist, Internal medicine, Addiction and Anxiety. His studies in Hallucinogen integrate themes in fields like Anesthesia, Salvinorin A and Crossover study.
His work on Migraine as part of general Anesthesia research is frequently linked to Mint family, bridging the gap between disciplines. His Psychiatry research incorporates elements of Distress and MEDLINE. His research investigates the connection with Caffeine and areas like Mean age which intersect with concerns in Substance abuse.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
R. R. Griffiths;W. A. Richards;U. McCann;R. Jesse.
Caffeinated energy drinks--a growing problem.
Chad J. Reissig;Eric C. Strain;Roland R. Griffiths.
Drug and Alcohol Dependence (2009)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Roland R Griffiths;Matthew W Johnson;Michael A Carducci;Annie Umbricht.
Journal of Psychopharmacology (2016)
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
Roland R. Griffiths;William A. Richards;Matthew W. Johnson;Una D. McCann.
Journal of Psychopharmacology (2008)
Human hallucinogen research: guidelines for safety.
Matthew W. Johnson;William A. Richards;Roland R. Griffiths.
Journal of Psychopharmacology (2008)
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
Katherine A MacLean;Matthew W Johnson;Roland R Griffiths.
Journal of Psychopharmacology (2011)
A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features.
Laura M. Juliano;Roland R. Griffiths.
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Roland R. Griffiths;Matthew W. Johnson;William A. Richards;Brian D. Richards.
Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction
Matthew W Johnson;Albert Garcia-Romeu;Mary P Cosimano;Roland R Griffiths.
Journal of Psychopharmacology (2014)
Withdrawal syndrome after the double-blind cessation of caffeine consumption.
Kenneth Silverman;Suzette M. Evans;Suzette M. Evans;Eric C. Strain;Roland R. Griffiths.
The New England Journal of Medicine (1992)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: